 | Up a level |
Journal Article
Bruns, H., Bittenbring, J. T., Mougiakakos, D., Fabri, M., Buettner, M., Pasemann, S., Kempkes, B., Mackensen, A. and Gerbitz, A. (2014). Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high grade B-cell lymphoma. Oncol. Res. Treat., 37. S. 70 - 71. BASEL: KARGER. ISSN 2296-5262
Bruns, H., Boettcher, M., Qorraj, M., Fabri, M., Jitschin, S., Dindorf, J., Busch, L., Jitschin, R., Mackensen, A. and Mougiakakos, D. (2017). CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D. Leukemia, 31 (4). S. 985 - 989. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Bruns, H., Buettner, M., Mougiakakos, D., Bittenbring, J., Beier, F., Pasemann, S., Fabri, M., Neumann, F., Mackensen, A. and Gerbitz, A. (2015). Vitamin D promotes tumoricidal activity of macrophages and improves the efficacy of antibody-dependent cellular cytotoxicity. Oncol. Res. Treat., 38. S. 95 - 96. BASEL: KARGER. ISSN 2296-5262
Busch, L., Mougiakakos, D., Bach, C., Buettner-Herold, M., Bittenbring, J. T., Neumann, F., Beier, F., Bisht, S., Nolting, J., Boettcher, M., Pallasch, C., Boxhammer, R., Spriewald, B. M., Mackensen, A. and Bruns, H. (2018). Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Oncol. Res. Treat., 41. S. 187 - 189. BASEL: KARGER. ISSN 2296-5262
Haanen, J., Mackensen, A., Koenecke, C., Alsdorf, W., Desuki, A., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Wiegert, E., Schulz, C., Rengstl, B., Preussner, L., Tuereci, O. and Sahin, U. (2021). BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors. Ann. Oncol., 32. S. S1392 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Bokemeyer, C., Klobuch, S., Smit, E., Mueller, F., Desuki, A., Lueke, F., Wiegert, E., Flemmig, C., Schulz-Eying, C., Rengstl, B., Preussner, L., Tuereci, O. and Sahin, U. (2022). BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours. Ann. Oncol., 33 (7). S. S1404 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041